Clinical study on the efficacy and safety assessment of BlephEx treatment for blepharitis and meibomian gland dysfunction

Clinical study on the efficacy and safety assessment of BlephEx treatment for blepharitis and meibomian gland dysfunction - Clinical study for blepharitis and meibomian gland dysfunction

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1092220338

Enrollment

Registered

2018-04-02

Start date

2018-08-31

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

blepharitis and meibomian gland dysfunction

Interventions

Intervention type:DEVICE Name of intervention:intervention of eye lid Dose form / Japanese Medical Device Nomenclature:DEVICE Route of administration / Site of application:OTHER Dose per administratio

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who are 18 years of age or older who are suspected of blepharitis or meibomian gland dysfunction

Exclusion criteria

Exclusion criteria: Patients with acute conjunctivitis, severe allergy, eyelid cleft wound, corneal structural vulnerability

Design outcomes

Primary

Measure	Time frame
Amount of debris of the eyelashes root	—

Secondary

Measure	Time frame
Meibomian gland infarction	—

Countries

Japan

Contacts

Public ContactKoji Niimi

Ishinkai Group Niimi Eye Institute

k@ocular.net+81-78-949-5310

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026